HERVolution Therapeutics, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for oncology, metabolic diseases, and longevity, today announced the ...
Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical ...
Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence ...
Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Immunic Inc. IMUX on Tuesday announced it appointed Michael Panzara as its Chief Medical Officer, effective April 24, 2026, as the company looks to advance its clinical and regulatory strategy. The ...
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight The follicular lymphoma clinical trial analysis report delivers important insights into ...
In today’s ACT Brief, we highlight where AI is delivering real gains in protocol development, how geopolitical disruption is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results